SCHEMBL675988

SCHEMBL675988

Cn1c(=O)c2c([S+](C)[O-])n(Cc3ccc(-n4cncn4)cc3)nc2n(CC(C)(C)C)c1=O

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.38
CYP11B2 P19099 1/20 0.34
PDE1B Q01064 3/20 0.33
PDE2A O00408 1/20 0.33
PDE4D Q08499 1/20 0.33
ABCC8 Q09428 1/20 0.32
KCNJ11 Q14654 1/20 0.32
DPP8 Q6V1X1 1/20 0.31
PDE1A P54750 1/20 0.30
PDE1C Q14123 1/20 0.30
BRS3 P32247 1/20 0.30
GRM2 Q14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680327 0.84 SMN1; SMN2 (0.39) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL676509 0.84 DPP4 (0.39) DPP4CYP11B2PDE1BPDE2APDE4D
SCHEMBL674792 0.83 DPP4 (0.38) DPP4CYP11B2PDE1BPDE2APDE4D
SCHEMBL676382 0.82 PDE1B (0.48) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL2120812 0.81 PDE1B (0.50) DPP4CYP11B2PDE1BPDE2APDE4D
SCHEMBL676325 0.81 DPP4 (0.37) DPP4CYP11B2PDE1BPDE2APDE1A
SCHEMBL680333 0.80 PDE1B (0.43) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL675682 0.77 DPP4 (0.41) DPP4CYP11B2PDE1BPDE2AABCC8
SCHEMBL2122099 0.74 PDE1B (0.42) DPP4CYP11B2PDE1BPDE2APDE4D
SCHEMBL2119987 0.74 PDE1B (0.42) DPP4CYP11B2PDE1BPDE2APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
EP-2367430-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2014-08-13 EP disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
WO-2010065152-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281832-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 DPP4 99/4885CYP11B2 66/4885PDE1B 4855/4885
US-20150119370-A1 Organic Compounds CYP2C19, CYP2C9, CYP3A43 DPP4 1117/4885CYP11B2 27/4885PDE1B 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.